Five of the world’s biggest drugs companies have agreed to slash the price of
their anti-HIV drugs in developing countries by 85 per cent following sustained
pressure from health agencies, Third World governments and patient groups
(New Scientist, 29 April, p 14).
One of the companies, Glaxo Wellcome, is
cutting the price of triple drug therapy from $16 to $2 a day. But
pressure groups have warned that even at these prices, poverty and a lack of
health infrastructure in poor countries will mean the benefits are limited.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
ÎçÒ¹¸£Àû1000¼¯ºÏ
No young women have died of cervical cancer in England for years
News
ÎçÒ¹¸£Àû1000¼¯ºÏ
Chilling the body with drugs could limit brain damage from stroke
News
Comment
The bigger the lizard, the bigger the Wiki page, discovers ecologist
Regulars
Technology
New Scientist recommends an excellent look at the future of work
Culture
Popular articles
Trending New Scientist articles
1
A quantum state that lasts forever may finally be within our grasp
2
The secrets to keeping your brain sharp in old age
3
The last-ditch plan to save coral reefs from utter destruction
4
Sperm have been made magnetic to allow IVF inside the body
5
Our brains have their first thoughts surprisingly early in life
6
Autism may have two distinct subtypes that vary by brain activity
7
The relationship recession is even bigger for Gen Z than we thought
8
Fully autonomous drones have killed human soldiers for the first time
9
Are we getting to the point where it's safe to gene-edit babies?
10
Has the answer to life's origins been hiding in our cells all along?
